Stromal-epithelial interaction contributes to local prostate tumor growth, androgen-independent progression and distant metastasis. We have established in vitro coculture and in vivo chimeric tumor models to evaluate the roles of stromal cells isolated from either osteosarcoma or normal bone, a site where prostate cancer cells frequently metastasize, in contributing to the growth and survival of human prostate cancer cells. We have evaluated extensively the effects of toxic gene therapy using luciferase-tagged chimeric human prostate cancer models both in vitro and in vivo. In the in vitro cocultured cell model, we assessed cancer cell growth and residual cellular proteins after targeting either prostate cancer epithelial cells alone or both prostate cancer and bone stromal cells. In the in vivo animal model, we measured tumor volume and serum prostate-specific antigen (PSA) in mice bearing chimeric prostate tumors comprised of human prostate tumor cells and normal bone stromal cells. Our results demonstrated that: (1) The rate of human prostate cancer cell growth in vitro is accelerated by coculturing with human and rat osteosarcoma or normal mouse bone marrow stromal cell lines. No growth stimulation was noted when cocultured with a human prostate epithelial cell line. (2) Disabling the growth of normal bone stromal cells using transgenic targeting with a bystander gene, herpes simplex virus thymidine kinase (hsv-TK), plus the pro-drug ganciclovir (GCV) or acyclovir markedly depressed the growth of cocultured human prostate cancer cells in vitro and human prostate cancer-mouse normal bone stroma chimeric tumors in vivo. (3) By cotargeting both human prostate cancer and normal mouse bone stromal cells in vitro with an adenoviral construct, Ad-hOC-TK (a replication-defective Ad5 vector with the bystander transgene hsv-TK under the control of a human osteocalcin (hOC) promoter) plus GCV 4 , we observed greater inhibition of tumor cell growth than by targeting a single cell compartment with Ad-PSA-TK (a vector construct similar to Ad-hOC-TK except that the transgene expression is under regulation by a full-length human PSA promoter). These results, taken together, established a basic principle that cotargeting both tumor and its supporting stroma is more efficacious than targeting a single cell compartment in the treatment of human prostate cancer bone metastasis. This principle can be applied to other clinical conditions of cancer growth where stroma contribute to the overall growth and survival potential of the cancer.
I
t has become increasingly clear that tumor-stroma interaction plays a role in supporting embryonic development and regulating growth, maturation and maintenance of the differentiated state in the adult and aging prostate gland. 1, 2 Aberrant interaction between tumor and stroma has been demonstrated to initiate neoplastic progression of prostate, 3, 4 breast, 5 gastrointestinal 6 and salivary 7 cancers. Using experimental cell models of prostate cancer and tissue recombinant techniques, our laboratory 8, 9 and others 4,10 demonstrated the pivotal importance of prostate and bone stromal cells in conferring growth, androgen-independence and/or bone metastatic properties to human prostate cancer cells in vivo. Human prostate cancer preferentially metastasizes to bone, and several laboratories have reported reciprocal cellular interaction between prostate cancer and bone 11, 12 and suggested the involvement of soluble and insoluble mediators contributing to this intercellular communication. 13 These observations raise the possibility of identifying new molecular targets for the treatment of prostate cancer bone metastasis, 14, 15 a common metastasis seen clinically in men that contributes significantly to patient mortality and morbidity.
Current therapeutic approaches use hormones, chemotherapy or molecular-targeting strategies focused primarily on tumor epithelium. These forms of therapy are highly effective but unfortunately not long lasting, and patients eventually become refractory to these therapeutic interventions. New approaches are badly needed to treat prostate cancer metastasis. One such approach is to consider prostate cancer as an organ consisting of both tumor epithelium and supporting prostate stroma when in the primary, or bone stroma after metastasis to bone, 16, 17 and associated neovasculature. 18 While the importance of tumor angiogenesis is well appreciated and the concept of cotargeting both tumor and neovasculature is well accepted, there has been little progress in cotargeting tumor and its associated stroma in experimental and clinical settings. Matsubara et al 19 showed that cotargeting tumor and stroma using a replicating adenoviral vector with viral replication controlled by a tissue-specific and tumor-restrictive promoter, osteocalcin (OC), resulted in 40% cure of mice with pre-established human prostate cancer in bone. Recently, attractive clinical approaches have achieved significant survival advantages when patients were treated by cotargeting cancer and bone. 20 For this communication, we tested the idea of cotargeting tumor and stroma in an experimental cell model of prostate cancer and metastasis both in vitro in a coculture model and in vivo in a chimeric tumor model. Results of this study support our hypothesis that more effective tumor growth control is achieved when therapeutic toxic gene is delivered to both tumor and stroma.
Materials and methods

Cell lines and cultures
LNCaP is an androgen-dependent human prostate cancer cell line originally derived from a supraclavicular lymph node with prostate cancer metastasis, from which we derived C4-2, an androgen-independent (AI) metastatic subline, using a cell recombination technique as described previously. 8 A number of human and murine bone stromal cell lines were chosen to study human prostate cancer-bone stromal interaction. MG-63, a human osteosarcoma cell line with osteoblastic lineage, was purchased from ATCC (Rockville, MD); ROS, a rat osteoblastic osteosarcoma cell line, was kindly provided by Dr Cindy Farach-Carson at the University of Delaware; and MS, a human osteoblastic cell line, was derived from an osteogenic sarcoma. All human and rat osteosarcoma cell lines were grown in T medium (Gibco, Grand Island, NY) with 5% fetal bovine serum (FBS). We also used a pluripotent normal bone stromal cell line, D1, derived from a ''blow-out'' bone marrow preparation of BALB/c mice as described previously. 21 D1 was maintained in DMEM with low glucose (Gibco) supplemented with 50 mg/ml L-ascorbic acid (Sigma, St Louis, MO) and 10% FBS.
Plasmid and virus construction
A 3.9-kb human osteocalcin (hOC) promoter was cloned from genomic DNA of DU145, an AI prostate cancer cell line, using Genome Walker kits (Clontech, Palo Alto, CA). A 6.1-kb prostate-specific antigen (PSA) promoter was kindly provided by Dr Jan Trapman (Rotterdam, The Netherlands). hOC and PSA promoter fragments, herpes simplex virus thymidinie kinase (hsv-TK) cDNA, and SV40 polyadenylation signal were inserted into the E1A-deleted region of a modified Ad5 adenovirus. AdhOC-TK stock was constructed, characterized and generated by Dr Frank Graham's laboratory (McMaster University, Ontario, Canada) using 293 cells; both therapeutic Ad-hOC-TK and Ad-PSA-TK were generated and expanded in 293 cells by cotransfecting these cells with both the expression shuttle plasmid and a circular Ad genome plasmid (pJM17). After transfection, cells were cultured in agarose medium for up to 10-12 days to allow plaque formation. Individual plaques were picked up and screened by the PCR method. Recombinant Ad vectors obtained from the selected plaques were amplified and purified according to the method of Graham and Prevec. 22 All Ad vectors were evaluated by particle count as determined by optical density measurement of DNA and titered by plaque assay.
In vitro cytotoxicity assays
Cells were seeded onto 24-well plates and infected with Ad vectors in the range of 0-100 MOI (multiplicity of infection). After 2 hours adsorption, the virus-containing medium was replaced with fresh medium. After 24 hours, cells were incubated in the presence or absence of 10 mg/ml ganciclovir (GCV) for a period of 5 days followed by crystal violet staining. The relative cell number was assessed by optical density (OD) at 590 nm after staining and calculated as fold of uninfected cells. Each experiment was carried out either in duplicate or triplicate.
In vitro coculture model
A luciferase-tagged C4-2 cell clone (C4-2-Luc) was generated by transfecting C4-2 with a plasmid DNA containing a luciferase gene driven by a cytomegalovirus promoter. . After 24 hours, cells were incubated in the presence or absence of 10 mg/ml GCV for a period of 4 days. C4-2-Luc cell number was estimated by measuring luciferase activity by an established procedure. 24 Total protein content was measured following the manufacturer's protocol using a BCA protein assay kit (Pierce, Rockford, IL). Each experiment was carried out either in duplicate or triplicate.
In vivo chimeric tumor model
The chimeric tumors were established subcutaneously in CD1 (nu/nu) athymic mice (Charles River, MA) by coinjecting a half-million C4-2 cells and a half-million normal mouse bone marrow stromal D1-TK cells suspended in 100 ml of DMEM with 10% FBS medium. Once tumors were formed with elevated serum PSA, mice were randomized and administered with 100 ml acyclovir (ACV) (40 mg/kg body weight) or PBS daily via intraperitoneal route for 3 weeks. Serum PSA of the control and treated mice was assessed at the end of the experimental period. Tumors were also assessed by a Faxitron X-ray machine for the growth of prostate and bone cells, and assessed histomorphologically at the time of animal sacrifice using previously described histochemical staining procedures. 25 
Statistical analysis
Differences between treatment groups were analyzed using Student's t-test and two-tailed distribution.
Results
Growth of human prostate cancer cells in vitro is stimulated by bone stromal cells
To distinguish the growth of human prostate cancer epithelial cells from mixed cell populations, we tagged the C4-2 cells stably with luciferase gene (C4-2-Luc) prior to mixing them with various bone stromal cell lines. As a control, the growth of C4-2-Luc cells was also measured in the presence of parental C4-2 cells. Figure 1a shows the linear relationship between luciferase enzymatic activity and C4-2-Luc cell number (from 10 2 to 10 6 cells). C4-2-Luc cell growth was stimulated markedly by MS and MG-63 cells (3-5-fold, Po.005) and significantly by D1 and ROS (Po .05) but not C4-2 cells (Fig 1b) . These data were confirmed by crystal violet and total cellular protein assays (data not shown) in which cell numbers were correlated as described previously 19, 26 and are supported also by published data on the coculture of prostate cancer and bone stromal cells. 8, 9 Because of the established intrinsic bone-forming property of the normal mouse osteoblastic D1 cell line when inoculated in vivo, we used this cell line stably transduced with hsv-TK gene for the subsequent in vivo studies.
The growth stimulatory effect of bone stromal cells on human prostate cancer epithelial cells is abrogated upon elimination of bone stromal cells in vitro
To determine if the growth stimulatory effect of D1 cells on C4-2-Luc is blocked by the elimination of D1 cells, we cocultured C4-2-Luc with a constant number of D1 þ D1-TK cells (but with increasing D1-TK cells from 0.4 to 2.0 Â 10 4 cells). As expected, the growth of C4-2-Luc increased upon coculture of C4-2 with D1 cells (Fig 2) . Upon the addition of the prodrug GCV, required for activation of the suicide hsv-TK gene now resident within the D1-TK cells, we observed a decreased growth of C4-2-Luc, both in luciferase activity and in total cellular protein extracted, in a D1-TK/D1 cell ratio-dependent manner. These results suggest that the growth of prostate cancer epithelial cells is profoundly affected by the elimination of their supporting stromal fibroblasts via the activation of a ''bystander'' hsv-TK gene. Because of the absence of gap junctions between D1-TK and C4-2-Luc as examined by electron microscopy and by dye transfer assay (data not shown), the most probable explanation of the ''bystander'' cytotoxicity we observed is the metabolic dependency between prostate cancer and bone stroma. Hence, when stroma cells are eliminated, prostate cancer epithelial cell growth is markedly retarded. Alternatively, direct uptake of metabolic products of TK enzyme from stromal to epithelial cells via hemi-junctions or transferred directly as apoptotic vesicles is also a possibility. 27 Inhibition of chimeric C4-2/D1-TK tumor growth in athymic mice
To develop a tumor model for observing rapid tumor growth and for convenient radiographic imaging, we established an in vivo chimeric cell model where C4-2 cells were coinoculated with D1-TK cells. As shown in Figure 3a and b, mice inoculated with D1-TK or D1-TK plus C4-2 grew tumors with a bone component, clearly revealed by radiographic and histomorphologic evidence. On intraperitoneal administration of the prodrug ACV, rapid shrinkage of tumor and marked decrease in serum PSA were observed (Fig 3a and c) . These results are consistent with the in vitro observation that elimination of prostate-cancer-associated bone stromal cells markedly inhibited prostate cancer cell growth in vitro (see Fig 2) .
Inhibition of both prostate cancer and bone stromal cell growth in vitro by Ad-hOC-TK/GCV but not Ad-PSA-TK/GCV To accomplish the goals of delivering therapeutic toxic gene directly to prostate cancer and bone stromal cells, we designed in vitro studies to test the possibility of cotargeting prostate cancer and supporting bone stroma using an adenoviral-based gene therapy approach with the expression of therapeutic toxic gene under the control of tissue-specific and cell-type-dependent promoters. We sought to test and compare promoters that are activated only in prostate cancer cells (such as PSA promoter) or in both prostate cancer and bone stromal cells (such as hOC promoter) in either single cell type or in the coculture of two dissimilar cell types. Figure 4 shows that, as expected, Ad-hOC-TK/GCV effectively inhibited the growth of both prostate cancer and bone stromal cells whereas Ad-PSA-TK/GCV was only effective in inhibiting the growth of prostate cancer but not bone stromal cells. To evaluate and compare the effectiveness of Ad-hOC-TK/GCV and Ad-PSA-TK/GCV in human prostate cancer and bone Animal model cotargeting tumor and stroma C-L Hsieh et al stromal cell cocultures, we infected either D1, C4-2-Luc, or both with either Ad-hOC-TK or Ad-PSA-TK prior to mixing them for coculture and addition of the prodrug GCV. As revealed in Figure 5 , Ad-hOC-TK/GCV inhibited the growth of C4-2-Luc cells when infected into either or both cellular compartments whereas Ad-PSA-TK/GCV was only effective when infecting the C4-2-Luc but not the D1 cell compartment (Fig 4) . Overall the effectiveness of Ad-hOC-TK/GCV was greatest when infecting both cellular compartments whereas a similar degree of cell growth inhibition was noted when Ad-PSA-TK/GCV was applied to either single or both cellular compartments (Fig 5) .
Discussion
The growth and metastasis of prostate cancer cells are intimately affected by their microenvironment because of the well-established autocrine, paracrine and endocrine communication loops existing between cancer cells and their adjacent microenvironment. 1, 12 In previous reports, we proposed that cancer growth can be interrupted most effectively by cotargeting both cancer epithelium and bone stroma cell compartments. 19 In the present communication, we used coculture and coinoculation systems to establish two cancer growth models and subsequently assessed the growth inhibition induced by a ''bystander'' toxic gene, hsv-TK, in the presence of a prodrug, GCV or ACV. hsv-TK was introduced in cells either by retroviral or adenoviral vectors. The results of our study demonstrated that: (1) Human prostate cancer epithelial growth is stimulated by coculture with either osteosarcoma or normal bone marrow stromal cells. (2) Interrupting normal bone marrow stromal cell growth using a toxic gene, hsv-TK, in the presence of the prodrug GCV or ACV, markedly inhibited prostate cancer cell growth in vitro and chimeric tumor growth in vivo. (3) Ad-hOC-TK/ GCV was more effective than Ad-PSA-TK/GCV in exerting a ''bystander'' cell-kill effect on the cocultured prostate cancer and bone stromal cells because of its dual targeting capability where the growth of both human prostate cancer cells and its supporting normal bone marrow stromal cells was affected.
The rationales of cotargeting prostate cancer and bone stroma in the treatment of prostate cancer bone metastasis are: (1) 36 have been shown to be potent autocrine/paracrine growth factors secreted by cancer cells and/or their supporting stroma, promoting the growth and survival of prostate cancer cells, osteoblasts and increased coupling between osteolytic and osteoblastic reactions. (2) Stromal secreted extracellular matrices and matrix metalloproteases 13, 37, 38 are known to support the growth, survival and invasion of prostate cancer epithelium. Figure 4 Ad-hOC-TK has a broader spectrum of cell-kill than Ad-PSA-TK. Cytotoxicity of both human prostate cancer and bone stromal cells by Ad-hOC-TK but not Ad-PSA-TK. C4-2 and D1 cells were exposed to Ad-hOC-TK or Ad-PSA-TK at the indicated dosage followed by incubation in the presence or absence of GCV. Cytotoxicity assay was performed at day 5 after infection in triplicate. The relative cell number is presented as the mean7SD of OD read in the GCV-treated versus control group. *Po.05 versus un-infected group. between prostate cancer and bone stroma increases the overall malignant potential, that is, growth, survival and invasion, of prostate cancer epithelial cells. 11, 12, 17 Prostate cancer cells are osteomimetic. They synthesize and deposit a number of osteoblast-specific proteins 39 and can actually form mineralized bone under appropriate growth conditions. 40 Thus, blocking the growth of both cancer and stroma using gene therapeutic targeting strategy under the control of tissue-specific and tumor-restrictive promoters should achieve optimal control of growth, invasion and metastasis of prostate cancer. This treatment strategy may also increase the susceptibility of cancer cells to concurrent therapy including hormone, radiation and chemotherapy.
In the present study, we have established an attractive new chimeric tumor model for the study of human prostate cancer and normal bone marrow stromal cellular interaction both in vitro and in vivo. We observed 100% incidence of chimeric tumors that formed rapidly in athymic mice with distinct histomorphologic osteoblastic and osteolytic reactions at 8-12 weeks by coinoculating a human prostate cancer cell line, C4-2 and a normal mouse bone marrow stromal cell line, D1 subcutaneously. This model is a valuable addition to the current animal models available for the study of prostate cancer growth and dissemination. Nemeth et al 10 demonstrated that in a severe combined immunodeficient human model there is a species-specific mechanism accountable for the homing and growth of human prostate cancer cells in human but not mouse bone. Several established rat models of prostate cancer, either hormonally and/or chemically induced, such as the Lobund Wistar or Nobel rat models 41, 42 are extremely valuable for the analysis of multi-step carcinogenesis. In these models, the time frame to form adenocarcinoma is 12-24 months. Spontaneous adenocarcinomas develop in the rat Dunning tumor model (R-3327), which is propagated both as cell lines and transplantable tumors in syngeneic Copenhagen rats. 43 Several laboratories have created transgenic models in which prostate adenocarcinomas develop with a high degree of frequency. 44, 45 Most of these models are based on the expression of SV40-T antigen in prostate epithelium. Thus, a potential limitation of these models is the use of a transgene not directly involved in human prostate cancer and the observed low frequency at which animals develop bone metastasis.
The bystander effect of hsv-TK/GCV gene therapy strategies has a demonstrated ability to augment tumor regression in several experimental models and has been proposed to result from transfer of an activated, phosphorylated, highly charged GCV molecule (GCV-P*) between cells via either gap junctions 46 or phagocytosis of apoptotic vesicles containing GCV-P* from dying hsv-TK þ cells. 47 Although the enzyme/prodrug system has been shown to be highly active within homotypic tumors, the heterotypic bystander effect between different cell types such as stroma and epithelium has not been explored. Although electron microscopic evidence indicates a lack of gap junctions between heterotypic prostate cancer and normal mouse bone marrow stromal cells when cocultured in vitro, we observed, however, bidirectional dye transfers across gap junctions between prostate cancer cells and a large number of stromal cell types including normal prostate stromal and bone marrow stromal cells (Edlund et al, unpublished results). Based on the information analyzed, gap junctional communication may be established between lineage-unrelated heterotypic cell types through yet undefined mechanisms.
In the present study, we showed that Ad-hOC-TK with TK gene expression controlled by tissue-specific and tumor-restrictive OC promoter exerted bystander cell-kill despite the lack of demonstrable gap junctions between stroma and epithelium. Because of the low level of coxsackie and adenovirus receptor (CAR) associated with stroma (data not shown), one possible strategy to circumvent the low transduction efficiency of Ad-hOC-TK onto stromal cells (Fig 4b) is to expose the cells to vitamin D 3 , increasing the expression of bystander toxic gene expression under the control of hOC promoter 26 through the VDR complex with VDRE in the proximal region of hOC promoter. In addition, vitamin D 3 is a well-known differentiating agent that may act like histone deacetylase inhibitors by restoring CAR expression. 48 Downregulation of CAR occurred frequently upon tumor progression. 49 Concomitant vitamin D 3 and AdhOC-TK may not only enhance transgene expression but also cellular susceptibility to Ad infection through increased CAR expression in tumors and their supporting stroma.
In summary, we have developed an experimental model both in vitro and in vivo to demonstrate the potent growth-stimulating role of normal bone marrow stromal cells and osteosarcoma cells on AI human prostate cancer cells and have validated a cotargeting strategy, targeting both cancer and its supporting stroma for the treatment of prostate cancer bone metastasis. Our study demonstrated the feasibility of using coculture and chimeric tumor models to study prostate cancer and bone stroma interaction and to explore the possible benefit of cotargeting prostate cancer and bone stroma. Results of our study revealed the benefit of cotargeting prostate cancer and bone stroma using a single tissue-specific and tumor-restrictive promoter, hOC, which drives the expression of a therapeutic toxic gene, hsv-TK, and exerts ''bystander'' cell-kill of prostate cancer cells by eliminating not only the growth of cancer cells directly but also the growth of their supporting stroma. Our ''proof-ofconcept'' study could be expanded in the future to test the idea of therapeutic cotargeting of both cancer and its supporting stroma using hormone, radiation and chemotherapy in combination with cytotoxic or immunemediated gene therapy.
